- Dr. Williams, a co-founder of the Algernon Pharmaceuticals drug repurposing program, was the company’s Chief Scientific Officer
- Dr. Williams has over 15 years of experience in drug and medical device development and has authored multiple patents
- He holds a Ph.D. in Microbiology from the University of Alberta, and an MBA from the University of Manitoba
- Algernon is a drug re-purposing company that investigates safe, approved drugs for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.09 per share
Algernon Pharmaceuticals (AGN) is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors.
Dr. Williams was a co-founder of the Algernon Pharmaceuticals drug repurposing program and was the company’s Chief Scientific Officer until March 1st, 2021. He has over 15 years of experience in drug and medical device development and has authored multiple patents. He has specific expertise and skillsets in taking companies from the discovery process to Phase 2 trials including cGMP manufacturing and toxicology. He holds a Ph.D. in Microbiology from the University of Alberta, and an MBA from the University of Manitoba.
“The company welcomes Mark back to Algernon as its newest Board member,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
“His extensive knowledge and background in pre-clinical and clinical drug development and biochemistry will add significant diversity to the skills and experience of our board.”
Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.09 per share.
